Supreme Court Reverses Federal Circuit on Induced Patent Infringement, Clarifying 'Skinny Label' Standard

The U.S. Supreme Court unanimously reversed a Federal Circuit decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., clarifying the standard for induced patent infringement. The ruling emphasizes that active encouragement of infringing use, rather than merely plausible interpretation of statements related to 'skinny labels,' is the relevant inquiry. This decision has significant implications for the pharmaceutical industry and patent law.